Intraperitoneal Chemotherapy in Ovarian Cancer
نویسندگان
1 Gynecology Oncology Department, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Gynecology Oncology Department, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 Gynecology Oncology Department, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Gynecology Oncology Department, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
5 Hematology Oncology Department, Vali-Asr Hospital ,Tehran University of Medical Sciences, Tehran, Iran
6 Gynecology Oncology Department, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
doi
10.5812/jogcr.64177چکیده
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer death in women. Primary surgery, followed by adjuvant chemotherapy is the basis of treatment for this disease. A standard treatment includes primary surgery and if possible optimal debulking surgery (tumor residue of <; 1 cm), followed by a chemotherapy; paclitaxel carboplatin is the standard regimen in ovarian cancer. Given that the main method of spreading this disease is in the peritoneal cavity, the systemic chemotherapy brings about numerous complications; moreover, as the method of prescribing a drug inside the peritoneum causes a high drug concentration in the peritoneal cavity, conducting an intraperitoneal chemotherapy has been examined clinically. In cases of ovarian cancer recurrence, performing a secondary cytoreductive surgery, in addition to hyperthermic intraperitoneal chemotherapy (HIPEC), has led to a good survival among patients. Currently, studies are ongoing to better explain the effects of this treatment method compared to previous methods.
